You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 2.2% | n/a |
Div Cover | 0.0 | n/a |
Op Mrgn | 2.8% | n/a |
ROCE | 7.0% |
Latest | Forecast | |
---|---|---|
P/E | 1,597.0 | n/a |
PEG | -16.5 | n/a |
Price / Revenue | 5.3 | n/a |
Price / Book value | 5.0 |
Latest | Forecast | |
---|---|---|
Revenue | 40.6% | 34.8% |
PBT | 0.0% | n/a |
EPS | -96.7% | -98.7% |
DPS | 2.5% | -98.6% |
Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2018-12-31 | 22,090.00 | 1,993.00 | $1.70 | 44.0 | -0.7 | -60% | $2.80 | 3.7% |
2019-12-31 | 24,384.00 | 1,548.00 | $1.03 | 97.9 | -2.5 | -39% | $2.80 | 2.8% |
2020-12-31 | 26,617.00 | 3,916.00 | $2.44 | 41.0 | 0.3 | 137% | $2.80 | 2.8% |
2021-12-31 | 37,417.00 | -265.00 | $0.08 | 1,467.0 | -15.2 | -97% | $2.87 | 2.4% |
Sector movers: Miners and Big Pharma drag Sharecast News | 01 Feb |
---|---|
AstraZeneca to buy US-based CinCor in $1.8bn deal Sharecast News | 09 Jan |
AstraZeneca gets new approvals in Japan on three drugs Sharecast News | 28 Dec |
Total Voting Rights | 01-Feb-23 23:58 |
---|---|
Update on Evusheld US EUA | 26-Jan-23 23:59 |
Acquisition of Neogene Therapeutics completed | 16-Jan-23 14:22 |
Airsupra (PT027) approved in US for asthma | 11-Jan-23 21:45 |
AstraZeneca acquire CinCor for cardiorenal asset | 09-Jan-23 14:09 |